HTB South

CROI (Retrovirus) 24 Seattle 2017

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

Increased risk of IRIS with integrase inhibitors reported in two studies

Dolutegravir exposure increases when fixed dose combination tablets are crushed

Dose reduction potential of nanoparticle ARV formulations confirmed in humans

Breakthrough for treating XDR-TB and ameliorating TB-IRIS

Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity

Adverse pregnancy outcomes and risk factors in the PROMISE trial

Pharmacokinetics, safety and efficacy of dolutegravir in very young children

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure modestly higher in children than adults

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

World Health Organisation paediatric dosing tool

Paediatric HIV: CROI 2017